Ciphergen Misled Investors, Class-Action Suit Alleges; Shares Slide 9 Percent | GenomeWeb

NEW YORK, Dec. 6 (GenomeWeb News) - A class action suit has accused Ciphergen Biosystems and certain of its officers and directors of misleading shareholders regarding its second quarter results, according to lawyers who filed the suit.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.